Despite vanadium compounds having insulin-mimetic properties, and the first report on their therapeutic properties about diabetes and dyslipidemia appeared in the 20th century [30, 31], its mode of action is still poorly understood at the molecular level [30, 32–39]. Here, INS is linked to metabolic syndrome.